Home Data Calendar Blog

NTLA

Tables

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Common Stock Value 0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.000.000.000.000.000.000.00
Weighted Average Number Of Diluted Shares Outstanding 76.0575.82NANA73.7168.16NANANANANANANANANANANANANANANANANA
Weighted Average Number Of Shares Outstanding Basic 76.0575.82NANA73.7168.16NANANANANANANANANANANANANANANANANA
Weighted Average Number Of Share Outstanding Basic And Diluted NANA74.75NA73.7168.1667.1861.3158.7553.3750.4949.3548.5545.8145.2344.2243.1642.8442.0439.1635.1934.9234.72
Earnings Per Share Basic NA-1.33NANANA-1.01NANANANANANANANANANANANANANANANANA
Earnings Per Share Diluted NA-1.33NANANA-1.01NANANANANANANANANANANANANANANANANA
Earnings Per Share Basic And Diluted NANA-1.96-1.10-0.97-1.01-0.69-0.69-0.47-0.61-0.63-0.57-0.49-0.56-0.49-0.43-0.53-0.52-0.51-0.61-0.44-0.45-0.36

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Revenue From Contract With Customer Excluding Assessed Tax 13.2714.0311.2512.857.206.556.456.5922.2216.2612.9210.9410.6211.1210.437.887.417.687.476.677.325.926.21
Revenue From Contract With Customer Including Assessed Tax 2.902.8011.2512.857.206.556.456.5922.2216.2612.9210.9410.6211.1210.437.887.417.687.476.677.325.926.21
Revenues 13.2714.0311.2512.857.206.556.456.5922.2216.2612.9210.9410.6211.1210.437.887.417.687.476.677.325.926.21
Costs And Expenses 118.80112.33155.5093.2779.2075.5752.8748.9950.3249.3045.9640.7135.9438.5834.2428.6331.5131.2729.9031.3823.1921.9319.16
Research And Development Expense 96.6590.20133.0971.1660.4958.8839.2838.2339.7637.7734.6531.7327.5125.4623.7119.9223.2423.4722.4921.1717.4815.5613.43
General And Administrative Expense 22.1422.1322.4022.1118.7116.6813.5910.7610.5711.5311.318.988.4313.1210.538.718.277.807.4110.215.716.375.73
Operating Income Loss -105.53-98.30-144.25-80.42-71.99-69.02-46.42-42.40-28.10-33.03-33.05-29.77-25.33-27.46-23.81-20.75-24.10-23.59-22.43-24.71-15.88-16.02-12.95
Allocated Share Based Compensation Expense 25.2123.0718.4914.5615.4110.616.425.585.404.764.163.023.084.404.593.584.464.904.116.603.252.852.63
Profit Loss -113.23-100.68-146.87-81.24-71.64-68.81-46.20-42.19-27.84-32.39-31.81-28.28-23.63-25.68-21.94-19.07-22.70-22.22-21.36-23.96-15.36NANA
Net Income Loss -113.23-100.68-146.87-81.24-71.64-68.81-46.20-42.19-27.84-32.39-31.81-28.28-23.63-25.68-21.94-19.07-22.70-22.22-21.36-23.96-15.36-15.59-12.63
Comprehensive Income Net Of Tax -113.04-102.17-152.30-83.69-71.81-68.81-46.22-42.22-27.96-32.61-31.69-28.35-23.55-25.49-21.85-19.09-22.70-22.22-21.36NANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Assets 1084.461110.421202.791294.461334.96672.24716.89676.32458.56490.83314.75334.28346.63352.44344.36347.31321.23339.78359.55376.24249.17264.98279.26
Liabilities And Stockholders Equity 1084.461110.421202.791294.461334.96672.24716.89676.32458.56490.83314.75334.28346.63352.44344.36347.31321.23339.78359.55376.24249.17264.98279.26
Stockholders Equity 824.95880.55953.751040.241107.10494.81545.87527.07329.62351.59247.76269.88275.65276.87264.34277.92263.27279.34295.50300.60175.85187.59199.88

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Assets Current 858.95895.43875.37769.30814.77549.40601.08616.52416.25446.37269.76289.48295.94307.14303.69324.98298.83317.63337.72354.83229.05245.92261.08
Cash And Cash Equivalents At Carrying Value 141.19147.78133.38123.41334.74129.88141.54160.02179.75361.6980.9957.2338.4449.1447.1058.86293.25305.54327.78340.68222.26241.05257.55
Marketable Securities Current 687.00726.49721.87625.28463.53399.14442.52437.35228.2075.12169.27222.50247.48221.96NA255.20NANANANANANANA
Accounts Receivable Net Current 4.022.851.802.032.491.990.952.131.223.8613.374.623.604.193.597.552.818.617.4710.474.492.762.44
Prepaid Expense And Other Assets Current 26.7318.3018.3218.5814.0218.3916.0717.027.095.706.135.136.414.713.523.372.773.482.483.682.302.111.08
Available For Sale Securities Debt Securities 707.53759.10861.36962.64813.98421.40459.26437.35228.2075.12169.27227.25257.35226.70249.49255.20NANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Property Plant And Equipment Net 26.6025.8723.7020.9719.9518.5316.1615.9415.6116.4017.2518.0017.2116.6916.6717.0616.9316.5816.0115.2713.5612.5811.42

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Liabilities Current 131.13123.76126.11125.8397.5773.9660.7064.2555.8759.1435.3035.6337.5238.4639.2340.5725.9125.1725.5831.3625.7926.3724.91
Accounts Payable Current 4.387.5110.149.657.476.858.6910.467.780.013.873.944.551.853.692.711.750.341.922.172.192.271.43
Other Accrued Liabilities Current 7.134.766.672.872.374.602.131.752.290.651.071.190.770.770.730.61NANANA0.68NANANA
Accrued Liabilities Current 58.3844.8742.8843.3124.6337.1521.2125.5519.3515.3713.1013.2711.6411.907.7410.749.899.166.618.005.945.313.56
Contract With Customer Liability Current 54.8261.8163.7663.7656.7622.5422.5422.5422.5437.9312.6412.6715.8219.6523.4327.1214.27NANA21.19NANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Other Liabilities Noncurrent NA10.7910.96NANANANANANANANANANANANA0.010.050.090.130.170.200.230.38
Operating Lease Liability Noncurrent 84.1060.0062.4864.9167.2763.2664.4933.6116.0017.3518.6712.63NANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Stockholders Equity 824.95880.55953.751040.241107.10494.81545.87527.07329.62351.59247.76269.88275.65276.87264.34277.92263.27279.34295.50300.60175.85187.59199.88
Common Stock Value 0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.000.000.000.000.000.000.00
Additional Paid In Capital Common Stock 1898.091840.641811.681745.871729.031044.941027.19962.17722.50716.50580.07570.49547.91525.57487.56478.97445.23438.59432.53421.71272.99269.38266.08
Retained Earnings Accumulated Deficit -1063.78-950.55-849.87-703.00-621.76-550.12-481.31-435.11-392.92-365.08-332.68-300.88-272.60-248.97-223.28-201.03-181.96-159.26-137.04-121.11-97.15-81.79-66.20
Accumulated Other Comprehensive Income Loss Net Of Tax -9.37-9.55-8.06-2.63-0.17-0.01-0.010.000.030.150.370.260.340.260.06-0.03NANANANANANANA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 25.2123.0718.49NA15.4110.616.42NA5.404.764.16NA3.084.404.59NA4.464.904.11NANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Net Cash Provided By Used In Operating Activities -78.53-85.09-79.80-54.65-65.02-52.98-52.38-40.23-28.5657.42-38.55-28.66-25.45-27.68-21.45-8.54-12.45-22.50-17.77-21.31-16.89NANA
Net Cash Provided By Used In Investing Activities 47.6495.3447.47-159.12-399.3833.26-25.54-210.92-153.9892.9657.4527.88-31.6523.255.70-256.02-2.02-0.90-1.85-2.40-2.26NANA
Net Cash Provided By Used In Financing Activities 23.985.8947.322.28668.687.1358.59234.090.60132.224.8619.5646.406.474.0030.162.181.166.72142.120.37NANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Net Cash Provided By Used In Operating Activities -78.53-85.09-79.80-54.65-65.02-52.98-52.38-40.23-28.5657.42-38.55-28.66-25.45-27.68-21.45-8.54-12.45-22.50-17.77-21.31-16.89NANA
Net Income Loss -113.23-100.68-146.87-81.24-71.64-68.81-46.20-42.19-27.84-32.39-31.81-28.28-23.63-25.68-21.94-19.07-22.70-22.22-21.36-23.96-15.36-15.59-12.63
Profit Loss -113.23-100.68-146.87-81.24-71.64-68.81-46.20-42.19-27.84-32.39-31.81-28.28-23.63-25.68-21.94-19.07-22.70-22.22-21.36-23.96-15.36NANA
Depreciation Depletion And Amortization 1.951.841.751.881.791.631.591.601.601.571.541.581.381.321.301.231.151.071.010.830.790.710.66
Increase Decrease In Accounts Receivable 1.171.05-0.23-0.460.501.04-1.180.91-2.65-9.508.751.02-0.590.60-3.964.73-5.801.14-3.005.981.730.32-4.01
Increase Decrease In Accounts Payable -1.62-3.65-0.062.400.74-1.69-0.921.617.34-3.53-0.37-0.032.20-1.651.360.301.53-1.660.06-0.260.440.28-0.95
Share Based Compensation 25.2123.0718.4914.5615.4110.616.425.585.404.764.163.023.084.404.593.584.464.904.116.603.252.852.63

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Net Cash Provided By Used In Investing Activities 47.6495.3447.47-159.12-399.3833.26-25.54-210.92-153.9892.9657.4527.88-31.6523.255.70-256.02-2.02-0.90-1.85-2.40-2.26NANA
Payments To Acquire Property Plant And Equipment 4.243.981.432.874.542.942.411.010.701.040.842.571.750.941.531.592.020.901.852.402.261.274.16

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Net Cash Provided By Used In Financing Activities 23.985.8947.322.28668.687.1358.59234.090.60132.224.8619.5646.406.474.0030.162.181.166.72142.120.37NANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31
Revenues 13.2714.0311.2512.857.206.556.456.5922.2216.2612.9210.9410.6211.1210.437.887.417.687.476.677.325.926.21
Avencell 5.705.705.605.780.12NANANANANANANANANANANANANANANANANANA
Avencell, Avencell Co Co Agreement 1.30-0.100.20-0.100.20NANANANANANANANANANANANANANANANANANA
Regeneron Pharmaceuticals Inc, Research And Development Services, Regeneron Arrangement 0.800.600.401.301.000.000.801.001.203.804.703.602.603.202.601.60NANANANANANANA
Regeneron Pharmaceuticals Inc, Hemophilia Co Co Agreements 3.202.201.500.601.101.00NANANANANANANANANANANANANANANANANA
Regeneron Pharmaceuticals Inc, Regeneron Arrangement 6.506.305.907.106.705.506.406.5022.2016.307.906.805.806.305.704.705.005.305.104.204.903.60NA
Kyvernalca NA2.00NANANANANANANANANANANANANANANANANANANANANA
Revenue From Contract With Customer Excluding Assessed Tax 13.2714.0311.2512.857.206.556.456.5922.2216.2612.9210.9410.6211.1210.437.887.417.687.476.677.325.926.21
Avencell 5.705.705.605.780.12NANANANANANANANANANANANANANANANANANA
Avencell, Avencell Co Co Agreement 1.30-0.100.20-0.100.20NANANANANANANANANANANANANANANANANANA
Regeneron Pharmaceuticals Inc, Research And Development Services, Regeneron Arrangement 0.800.600.401.301.000.000.801.001.203.804.703.602.603.202.601.60NANANANANANANA
Regeneron Pharmaceuticals Inc, Hemophilia Co Co Agreements 3.202.201.500.601.101.00NANANANANANANANANANANANANANANANANA
Regeneron Pharmaceuticals Inc, Regeneron Arrangement 6.506.305.907.106.705.506.406.5022.2016.307.906.805.806.305.704.705.005.305.104.204.903.60NA
Kyvernalca NA2.00NANANANANANANANANANANANANANANANANANANANANA
Revenue From Contract With Customer Including Assessed Tax 2.902.8011.2512.857.206.556.456.5922.2216.2612.9210.9410.6211.1210.437.887.417.687.476.677.325.926.21
Kyverna Therapeutics Inc 2.302.00NANANANANANANANANANANANANANANANANANANANANA
Avencellcoco 5.800.100.20NANANANANANANANANANANANANANANANANANANANA
Avencelllca 5.705.705.60-62.49125.00NANANANANANANANANANANANANANANANANANA

Plots across concepts


IncomeStatement
Net Income Loss
Expenses
Other Nonoperating Income Expense
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Property Plant And Equipment Net
Current Assets
Accounts Receivable Net Current
NonCurrent Assets
Property Plant And Equipment Net
Liabilities
Liabilities Current
Current Liabilities
Accounts Payable Current
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Income Loss
NetCashProvidedByUsedInOperatingActivities
Net Income Loss
NetCashProvidedByUsedInInvestingActivities
Payments To Acquire Businesses Net Of Cash Acquired
Shares
Weighted Average Number Of Share Outstanding Basic And Diluted
OperatingLeaseLiability
Operating Lease Liability Current

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap:RelatedPartyTransactionsByRelatedParty
(None,)
Revenue From Contract With Customer Including Assessed Taxus-gaap: Related Party Transactions By Related Party
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)
Allocated Share Based Compensation Expenseus-gaap: Income Statement Location
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Financial Instrument
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap:RelatedPartyTransactionsByRelatedParty
(None,)
Revenue From Contract With Customer Including Assessed Taxus-gaap: Related Party Transactions By Related Party